Essential thrombocythemia (ET) is characterized by abnormal megakaryopoiesis and enhanced thrombotic risk. Once-daily (od), low-dose aspirin is the recommended antithrombotic regimen, but accelerated platelet generation may reduce the duration of platelet cyclooxygenase (COX)-1 inhibition. We performed a multicenter, double-blind trial to investigate the efficacy of three aspirin regimens in optimizing platelet COX-1 inhibition while preserving COX-2-dependent vascular thromboresistance. Two-hundred-forty-five patients on chronic od low-dose aspirin were randomized (1:1:1) to receive 100 mg aspirin od, twice-daily, bid), or three-times daily (tid) for 2 weeks. Serum thromboxane B2 (sTXB2), a validated biomarker of platelet COX-1 activity, and urinary prostacyclin metabolite (PGIM) excretion were measured at randomization and after 2 weeks, as primary surrogate endpoints of efficacy and safety, respectively. Urinary TX metabolite (TXM) excretion, gastrointestinal tolerance, and ET-related symptoms were also investigated. Evaluable patients assigned to the bid and tid regimens showed substantially reduced inter-individual variability and lower median values of sTXB2: 19.3[9.7-40], 4 [2.1-6.7], and 2.5[1.4-5.65] ng/ml in the od (n=85), bid (n=79) and tid (n=79) arms, respectively. Urinary PGIM was comparable in the three arms. Urinary TXM was significantly reduced by 35% in both experimental arms. Patients in the tid arm reported a higher abdominal discomfort score. In conclusion, the currently recommended aspirin regimen of 75-100 od for cardiovascular prophylaxis appears largely inadequate in reducing platelet activation in the vast majority of ET patients. The antiplatelet response to low-dose aspirin can be markedly improved by shortening the dosing interval to 12 hours, with no improvement by further reducing it. (EudraCT 2016-002885-30).

A randomized, double-blind trial of three aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia / Rocca, Bianca; Tosetto, Alberto; Betti, Silvia; Soldati, Denise; Petrucci, Giovanna; Rossi, Elena; Timillero, Andrea; Cavalca, Viviana; Porro, Benedetta; Iurlo, Alessandra; Cattaneo, Daniele; Bucelli, Cristina; Dragani, Alfredo; Di Ianni, Mauro; Ranalli, Paola; Palandri, Francesca; Vianelli, Nicola; Beggiato, Eloise; Lanzarone, Giuseppe; Ruggeri, Marco; Carli, Giuseppe; Elli, Elena Maria; Carpenedo, Monica; Bertozzi, Irene; Paoli, Chiara; Randi, Maria L; Ricco, Alessandra; Specchia, Giorgina; Vannucchi, Alessandro Maria; Rodeghiero, Francesco; Patrono, Carlo; De Stefano, Valerio. - In: BLOOD. - ISSN 0006-4971. - ELETTRONICO. - (2020), pp. 1-33. [10.1182/blood.2019004596]

A randomized, double-blind trial of three aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia

Palandri, Francesca;Carli, Giuseppe;Paoli, Chiara;Ricco, Alessandra;Vannucchi, Alessandro Maria;
2020

Abstract

Essential thrombocythemia (ET) is characterized by abnormal megakaryopoiesis and enhanced thrombotic risk. Once-daily (od), low-dose aspirin is the recommended antithrombotic regimen, but accelerated platelet generation may reduce the duration of platelet cyclooxygenase (COX)-1 inhibition. We performed a multicenter, double-blind trial to investigate the efficacy of three aspirin regimens in optimizing platelet COX-1 inhibition while preserving COX-2-dependent vascular thromboresistance. Two-hundred-forty-five patients on chronic od low-dose aspirin were randomized (1:1:1) to receive 100 mg aspirin od, twice-daily, bid), or three-times daily (tid) for 2 weeks. Serum thromboxane B2 (sTXB2), a validated biomarker of platelet COX-1 activity, and urinary prostacyclin metabolite (PGIM) excretion were measured at randomization and after 2 weeks, as primary surrogate endpoints of efficacy and safety, respectively. Urinary TX metabolite (TXM) excretion, gastrointestinal tolerance, and ET-related symptoms were also investigated. Evaluable patients assigned to the bid and tid regimens showed substantially reduced inter-individual variability and lower median values of sTXB2: 19.3[9.7-40], 4 [2.1-6.7], and 2.5[1.4-5.65] ng/ml in the od (n=85), bid (n=79) and tid (n=79) arms, respectively. Urinary PGIM was comparable in the three arms. Urinary TXM was significantly reduced by 35% in both experimental arms. Patients in the tid arm reported a higher abdominal discomfort score. In conclusion, the currently recommended aspirin regimen of 75-100 od for cardiovascular prophylaxis appears largely inadequate in reducing platelet activation in the vast majority of ET patients. The antiplatelet response to low-dose aspirin can be markedly improved by shortening the dosing interval to 12 hours, with no improvement by further reducing it. (EudraCT 2016-002885-30).
2020
1
33
Goal 3: Good health and well-being for people
Rocca, Bianca; Tosetto, Alberto; Betti, Silvia; Soldati, Denise; Petrucci, Giovanna; Rossi, Elena; Timillero, Andrea; Cavalca, Viviana; Porro, Benedetta; Iurlo, Alessandra; Cattaneo, Daniele; Bucelli, Cristina; Dragani, Alfredo; Di Ianni, Mauro; Ranalli, Paola; Palandri, Francesca; Vianelli, Nicola; Beggiato, Eloise; Lanzarone, Giuseppe; Ruggeri, Marco; Carli, Giuseppe; Elli, Elena Maria; Carpenedo, Monica; Bertozzi, Irene; Paoli, Chiara; Randi, Maria L; Ricco, Alessandra; Specchia, Giorgina; Vannucchi, Alessandro Maria; Rodeghiero, Francesco; Patrono, Carlo; De Stefano, Valerio
File in questo prodotto:
File Dimensione Formato  
blood.2019004596.pdf

Open Access dal 01/01/2023

Tipologia: Pdf editoriale (Version of record)
Licenza: Open Access
Dimensione 1.82 MB
Formato Adobe PDF
1.82 MB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1196073
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 60
  • ???jsp.display-item.citation.isi??? 58
social impact